Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Ziftomenib + Imatinib

Stage Phase 1

Sponsor Kura Oncology

Class menin inhibitor (with imatinib)

Target Menin (TEC-0031)

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06655246

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06655246

Registry NCT06655246

Phase Phase 1

Status Recruiting

Enrollment 135

Start 2025-03-27

Primary completion 2029-06

Study completion 2030-06

Catalyst Primary completion. 06.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.